Genmab A/S (NASDAQ:GMAB) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Genmab A/S (NASDAQ:GMAB) have been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $45.20.

GMAB has been the topic of a number of analyst reports. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. Redburn Atlantic initiated coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They issued a “buy” rating on the stock. Morgan Stanley restated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research report on Wednesday, September 11th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research report on Wednesday, October 16th. Finally, Truist Financial decreased their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th.

Genmab A/S Stock Performance

NASDAQ GMAB opened at $22.33 on Thursday. Genmab A/S has a 1 year low of $21.90 and a 1 year high of $32.89. The business’s fifty day moving average is $24.57 and its two-hundred day moving average is $26.47. The stock has a market capitalization of $14.78 billion, a P/E ratio of 18.45, a P/E/G ratio of 0.68 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The company had revenue of $779.50 million for the quarter, compared to analyst estimates of $734.60 million. On average, research analysts forecast that Genmab A/S will post 1.29 earnings per share for the current year.

Institutional Trading of Genmab A/S

A number of institutional investors have recently bought and sold shares of GMAB. Russell Investments Group Ltd. increased its position in Genmab A/S by 137.7% in the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after purchasing an additional 544 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Genmab A/S in the 1st quarter valued at approximately $43,000. Blue Trust Inc. increased its holdings in Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after buying an additional 3,880 shares during the last quarter. Headlands Technologies LLC raised its position in Genmab A/S by 1,702.8% during the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. lifted its stake in Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after acquiring an additional 478 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.